Skip to main content
AAPL+0.24%MSFT+0.26%NVDA-0.37%GOOGL-4.07%AMZN+0.18%TSM-6.34%SPCX-1.26%META-0.33%AVGO-3.92%TSLA-0.19%LLY-0.82%BRK-B-0.02%WMT+0.25%JPM-2.31%SKHY-7.29%AMD-5.58%MU-0.14%V+0.16%XOM-2.12%JNJ-1.12%MA+0.08%ASMLa-2.51%ABBV-0.16%COST+0.68%1398.HK-0.77%0700.HK-3.15%KO+0.23%CVX-1.23%PG+1.96%CSCO-1.17%UNH+1.12%ORCL-5.03%0939.HK-0.23%HD-0.34%3988.HK-0.43%BAC-1.84%GE-2.00%0857.HK-0.38%1816.HK-28.86%1288.HK-1.33%0005.HK-1.02%PM-1.47%HSBA.L-0.37%NVS-0.19%INTC-7.07%MS-2.65%AZN-0.23%AP2d-0.61%AMAT-5.47%SAPd-0.02%NZDJPY-0.84%AUDJPY-0.75%CADJPY-0.54%NZDUSD-0.51%EURJPY-0.47%NZDCHF-0.46%AUDUSD-0.46%GBPJPY-0.44%GBPTRY+0.41%GBPNZD+0.40%AUDCHF-0.40%EURNZD+0.37%CHFJPY-0.36%USDJPY-0.32%GBPHKD+0.32%GBPAUD+0.31%EURAUD+0.31%NZDCAD-0.30%GBPMXN-0.28%USDCAD+0.23%AUDCAD-0.23%USDTHB-0.21%USDILS+0.16%CADCHF-0.16%USDSEK-0.16%EURUSD-0.15%USDCNH-0.14%GBPUSD-0.11%USDTRY+0.11%NZDMXN-0.11%USDZAR-0.11%GBPCAD+0.10%USDPLN-0.10%SGDJPY-0.09%EURCNH+0.09%EURCAD+0.09%CHFSEK-0.09%USDDKK-0.09%USDMXN-0.09%USDNOK-0.09%EURHKD+0.08%USDCHF+0.08%EURSEK-0.07%NZDSGD-0.07%EURCHF-0.07%NOKJPY-0.07%AUDNZD+0.06%USDSGD-0.06%PLNJPY-0.05%USDCOP-0.04%GBPCHF-0.04%GBPZAR-0.04%EURCZK-0.03%EURZAR-0.03%EURSGD+0.02%EURGBP-0.02%GBPSGD+0.02%AUDSGD+0.02%EURPLN-0.02%CHFNOK-0.01%CHFSGD+0.01%AUDDKK-0.01%AUDNOK-0.01%USDHKD+0.01%EURDKK0.00%EURNOK0.00%W1+2.02%XPTUSD+1.63%GAGUSD+1.17%XAGUSD+1.17%XNGUSD-0.58%GAUUSD+0.47%XAUUSD+0.47%UKOIL-0.32%USOIL-0.22%HG1-0.07%S1+0.04%C10.00%BTCUSD-0.79%ETHUSD+56.78%USDTUSD-0.07%XRPUSD+54.01%SOLUSD+62.71%TRXUSDT+0.37%ZECUSDT+0.72%XMRUSDT+0.26%DOGEUSD+56.51%LINKUSD-1.30%XLMUSD-2.05%BCHUSDT-0.95%LTCUSD+46.82%UNIUSD+1.34%SUIUSD-1.61%TONUSD+59.79%HBARUSDT-3.83%TAOUSDT-0.91%AAVEUSD+2.42%ONDOUSDT-1.45%ICPUSDT+10.12%DOTUSDT+0.23%WLDUSDT-2.34%ARBUSDT-2.08%INJUSDT+4.88%ATOMUSDT+1.33%STXUSDT-2.35%PYTHUSDT-2.90%TIAUSDT-1.38%FETUSDT-0.13%SEIUSDT-0.49%JUPUSDT-7.53%GRTUSDT-0.81%OPUSDT-4.21%IOTAUSDT-0.42%POLUSDT-0.24%WIFUSDT-0.04%AXSUSDT-2.03%EOSUSDT+0.36%FARTCOINUSDT-3.29%IMXUSDT-2.11%GALAUSDT-0.22%DYDXUSDT+1.11%ORDIUSDT-0.77%NOTUSDT+0.53%RONINUSDT-2.38%AAPL+0.24%MSFT+0.26%NVDA-0.37%GOOGL-4.07%AMZN+0.18%TSM-6.34%SPCX-1.26%META-0.33%AVGO-3.92%TSLA-0.19%LLY-0.82%BRK-B-0.02%WMT+0.25%JPM-2.31%SKHY-7.29%AMD-5.58%MU-0.14%V+0.16%XOM-2.12%JNJ-1.12%MA+0.08%ASMLa-2.51%ABBV-0.16%COST+0.68%1398.HK-0.77%0700.HK-3.15%KO+0.23%CVX-1.23%PG+1.96%CSCO-1.17%UNH+1.12%ORCL-5.03%0939.HK-0.23%HD-0.34%3988.HK-0.43%BAC-1.84%GE-2.00%0857.HK-0.38%1816.HK-28.86%1288.HK-1.33%0005.HK-1.02%PM-1.47%HSBA.L-0.37%NVS-0.19%INTC-7.07%MS-2.65%AZN-0.23%AP2d-0.61%AMAT-5.47%SAPd-0.02%NZDJPY-0.84%AUDJPY-0.75%CADJPY-0.54%NZDUSD-0.51%EURJPY-0.47%NZDCHF-0.46%AUDUSD-0.46%GBPJPY-0.44%GBPTRY+0.41%GBPNZD+0.40%AUDCHF-0.40%EURNZD+0.37%CHFJPY-0.36%USDJPY-0.32%GBPHKD+0.32%GBPAUD+0.31%EURAUD+0.31%NZDCAD-0.30%GBPMXN-0.28%USDCAD+0.23%AUDCAD-0.23%USDTHB-0.21%USDILS+0.16%CADCHF-0.16%USDSEK-0.16%EURUSD-0.15%USDCNH-0.14%GBPUSD-0.11%USDTRY+0.11%NZDMXN-0.11%USDZAR-0.11%GBPCAD+0.10%USDPLN-0.10%SGDJPY-0.09%EURCNH+0.09%EURCAD+0.09%CHFSEK-0.09%USDDKK-0.09%USDMXN-0.09%USDNOK-0.09%EURHKD+0.08%USDCHF+0.08%EURSEK-0.07%NZDSGD-0.07%EURCHF-0.07%NOKJPY-0.07%AUDNZD+0.06%USDSGD-0.06%PLNJPY-0.05%USDCOP-0.04%GBPCHF-0.04%GBPZAR-0.04%EURCZK-0.03%EURZAR-0.03%EURSGD+0.02%EURGBP-0.02%GBPSGD+0.02%AUDSGD+0.02%EURPLN-0.02%CHFNOK-0.01%CHFSGD+0.01%AUDDKK-0.01%AUDNOK-0.01%USDHKD+0.01%EURDKK0.00%EURNOK0.00%W1+2.02%XPTUSD+1.63%GAGUSD+1.17%XAGUSD+1.17%XNGUSD-0.58%GAUUSD+0.47%XAUUSD+0.47%UKOIL-0.32%USOIL-0.22%HG1-0.07%S1+0.04%C10.00%BTCUSD-0.79%ETHUSD+56.78%USDTUSD-0.07%XRPUSD+54.01%SOLUSD+62.71%TRXUSDT+0.37%ZECUSDT+0.72%XMRUSDT+0.26%DOGEUSD+56.51%LINKUSD-1.30%XLMUSD-2.05%BCHUSDT-0.95%LTCUSD+46.82%UNIUSD+1.34%SUIUSD-1.61%TONUSD+59.79%HBARUSDT-3.83%TAOUSDT-0.91%AAVEUSD+2.42%ONDOUSDT-1.45%ICPUSDT+10.12%DOTUSDT+0.23%WLDUSDT-2.34%ARBUSDT-2.08%INJUSDT+4.88%ATOMUSDT+1.33%STXUSDT-2.35%PYTHUSDT-2.90%TIAUSDT-1.38%FETUSDT-0.13%SEIUSDT-0.49%JUPUSDT-7.53%GRTUSDT-0.81%OPUSDT-4.21%IOTAUSDT-0.42%POLUSDT-0.24%WIFUSDT-0.04%AXSUSDT-2.03%EOSUSDT+0.36%FARTCOINUSDT-3.29%IMXUSDT-2.11%GALAUSDT-0.22%DYDXUSDT+1.11%ORDIUSDT-0.77%NOTUSDT+0.53%RONINUSDT-2.38%

FDA approves Novartis’ Cosentyx for PMR treatment

NEWS

November 17, 2026 at 03:20 UTC

4 min read
Unbranded injectable drug pen on clinical tray symbolizing FDA approval of new PMR treatment for NVS

Key Points

  • 01FDA approves Cosentyx 150 mg for adults with polymyalgia rheumatica
  • 02Cosentyx becomes first and only anti‑IL‑17 biologic FDA‑approved for PMR
  • 03Phase III REPLENISH trial showed Cosentyx doubled sustained remission vs placebo
  • 04Approval represents the 11th US indication for Cosentyx

FDA grants new PMR indication for Cosentyx

On November 17, 2026, the US Food and Drug Administration approved Novartis’ Cosentyx (secukinumab) 150 mg for the treatment of adult patients with polymyalgia rheumatica (PMR) who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper. The decision makes Cosentyx the first and only FDA‑approved anti‑IL‑17 biologic for people with PMR and represents the 11th US indication for the medicine.

The new indication targets a population in which long‑term reliance on steroids is common and where alternative options beyond glucocorticoids have been limited. The approval follows earlier authorization of the PMR indication in the European Union and comes as additional regulatory reviews are ongoing in other regions, including Japan.

Efficacy results from the REPLENISH Phase III trial

The FDA approval is supported by data from the global Phase III REPLENISH trial, a multicenter, randomized, double‑blind, placebo‑controlled, parallel‑group study conducted across 27 countries. In the trial, patients with PMR were randomized to receive Cosentyx 300 mg, Cosentyx 150 mg, or placebo, all in combination with a 24‑week steroid tapering regimen.

The primary endpoint was achieved with the Cosentyx 150 mg dose. Adults with PMR treated with Cosentyx 150 mg achieved sustained remission at week 52 at twice the rate of patients receiving placebo, with remission rates of 40.5% versus 20.5% following the steroid taper. Cosentyx also demonstrated steroid‑sparing effects compared with placebo in this setting.

Key secondary endpoints in the trial included the proportion of patients achieving complete sustained remission at week 52, the adjusted annual cumulative steroid dose, and the time to first use of escape or rescue treatment through week 52. Trial data were published in the New England Journal of Medicine and presented at the 2026 European Alliance of Associations for Rheumatology Congress.

Safety profile and adverse events in PMR

In the PMR study, the safety profile of Cosentyx remained consistent with its established profile across immune‑mediated diseases. Serious adverse events were reported in 15.9% of patients in the Cosentyx 150 mg group and in 14.2% of those in the placebo group.

Patients treated with Cosentyx 150 mg experienced higher proportions of hypersensitivity reactions, including eczema, dermatitis, rash, and urticaria, as well as urinary tract infections, compared with placebo. Hypersensitivity reactions occurred in 14% of Cosentyx‑treated patients versus 9% on placebo, and urinary tract infections in 13% versus 7%, respectively. One patient in the Cosentyx 150 mg group had a serious urinary tract infection, and a fatal case of cryptococcal meningitis occurred in a patient treated with Cosentyx.

PMR disease burden and role of Cosentyx

Polymyalgia rheumatica is described as a common inflammatory disease affecting adults aged 50 years and older, typically presenting with acute pain and stiffness in the shoulders, neck, and hips. In the United States, approximately 966,000 people are estimated to be living with PMR, and relapses are frequent, affecting up to 40% of patients in the first year.

PMR is commonly managed with steroids, but prolonged steroid use increases the risk of complications such as osteoporosis, cardiovascular disease, and diabetes. By directly inhibiting interleukin‑17A, Cosentyx offers a biologic option that can double sustained remission rates versus placebo while supporting steroid tapering, providing rheumatologists with an alternative to long‑term steroid therapy for eligible adult PMR patients.

Cosentyx within Novartis’ immunology portfolio

Cosentyx is a fully human biologic that directly targets interleukin‑17A, a cytokine involved in inflammation underlying multiple immune‑mediated inflammatory diseases. Beyond PMR, it is approved worldwide for adults with conditions such as psoriatic arthritis, moderate to severe plaque psoriasis, ankylosing spondylitis, non‑radiographic axial spondyloarthritis, hidradenitis suppurativa, and PMR.

Cosentyx also has approvals for use in pediatric patients, including those with plaque psoriasis, juvenile psoriatic arthritis, enthesitis‑related arthritis, and, in the United States, for patients aged 12 years and older with moderate to severe hidradenitis suppurativa and juvenile ankylosing spondylitis. The PMR indication extends its reach to a large and previously underserved patient group within the broader immunology space.

Key Takeaways

  • 01Cosentyx’s new PMR indication broadens treatment options for adults who cannot adequately manage the disease with steroids alone.
  • 02Phase III data show that targeting interleukin‑17A can both increase sustained remission and support steroid tapering in PMR.
  • 03Risk–benefit assessment for Cosentyx in PMR must weigh improved remission against higher rates of certain adverse events and rare serious infections.

FDA clears Cosentyx for PMR treatment | Trading Dashboard